Distribution and outcomes of patients that underwent allogeneic HSCT during first or second remission according to the ELN2017 genetic risk groups. (A) Distribution of the ELN2017 risk groups of patients who underwent allogeneic HSCT during the first or second CR/CRi. (B-D) CIR in patients with AML according to the number of CRs/CRis (first vs second) at allogeneic HSCT in the 3 ELN2017 genetic risk groups. ELN2017 favorable risk (B; n = 112), ELN2017 intermediate risk (C; n = 147), and ELN2017 adverse risk (D; n = 158). (E-G) Cumulative incidences of relapse of patients with AML according to the number of CRs/CRis (first vs second) and the MRD status at allogeneic HSCT (positive vs negative) in the 3 ELN2017 genetic risk groups. (E) ELN2017 favorable risk (n = 80), MRD⁺ vs MRD⁻: first CR/CRi (P = .21) and second CR/CRi (P = .003). (F) ELN2017 intermediate risk (n = 77), MRD⁺ vs MRD⁻: first CR/CRi (P = .02) and second CR/CRi (P = .002). (G) ELN2017 adverse risk (n = 83), MRD⁺ vs MRD-⁻: first CR/CRi (P = .06) and second CR/CRi (P = .81).